ORION NUTRACEUTICALS INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.4 CAD | -.--% |
|
-.--% | -.--% |
| 19/04 | Orion Nutraceuticals Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended February 29, 2024 | CI |
| 13/03 | Joel Dumaresq Resigns as Director of Orion Nutraceuticals Inc | CI |
| Sales 2022 | - | Sales 2023 | - | Capitalization | 11.72M 16.15M 978M |
|---|---|---|---|---|---|
| Net income 2022 | -2M -2.76M -167M | Net income 2023 | - 0 0 | EV / Sales 2022 | - |
| Net Debt 2022 | 34.57K 47.63K 2.88M | Net Debt 2023 | 86.34K 119K 7.21M | EV / Sales 2023 | - |
| P/E ratio 2022 |
-4.47
x | P/E ratio 2023 |
-41.9
x | Employees | - |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 98.64% |
More Fundamentals
* Assessed data
More news
More press releases
5 years
0.14
5.13
10 years
0.1425.00
| Members of the board | Title | Age | Since |
|---|---|---|---|
Guy Bourgeois
CEO | Chief Executive Officer | - | 07/23/07 |
Amanda Boudreau
BRD | Director/Board Member | - | 07/23/07 |
Orion Nutraceuticals Inc. is a Canada-based company. The Company is primarily focused on re-purposing a United States food and drug administration approved drug to target asthma and chronic obstructive pulmonary disease (COPD).
Sector
Pharmaceuticals
Calendar
26/09/2024
- Q4 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| -.--% | 8.68M | |
| +39.33% | 6.01B | |
| -18.38% | 4.4B | |
| -9.17% | 3.17B | |
| +3.98% | 3.07B | |
| -3.41% | 2.51B | |
| +48.74% | 1.88B | |
| -4.82% | 1.73B | |
| -1.24% | 1.65B | |
| -8.96% | 1.58B |
- Stock Market
- Equities
- ORI Stock
